+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Rheumatoid Arthritis Market (2021 Edition) - Analysis By Drug Type (NSAIDs, DMARDs, Corticosteroids, Others), Treatment, Diagnosis, By Region, By Country: Market Insights and Forecast with Impact of COVID-19 (2021-2026)

  • ID: 5504577
  • Report
  • November 2021
  • Region: Global
  • 220 Pages
  • Azoth Analytics

The Global Rheumatoid Arthritis Market was valued at USD 24.46 Billion in the year 2020. Globally, the market for rheumatoid arthritis is increasing rapidly and the major factors that drive the growth of rheumatoid arthritis is the increasing aging population. Furthermore, some evidence suggests that people who smoke are at an increased risk of developing rheumatoid arthritis.





DMARDs segment is expected to hold significant share in Rheumatoid Arthritis Market on the back of increasing prevalence of rheumatoid arthritis incidences across the globe, the launch of the therapeutic agents, and the favorable reimbursement policies for the high-cost treatment products. These are the major factors propelling the growth of the market.



Americas region dominated the global Rheumatoid Arthritis market and led the industry in 2020 owing to presence of large patient base and availability of well-developed infrastructure, rising awareness regarding disease treatment, growing geriatric population, and high adoption of biopharmaceuticals for treatment.



There is also an increase in funds provided to academic research institutions and individual researchers that is expected to boost the market growth. Moreover, various initiatives by international bodies, such as WHO and NIH for the prevention and treatment of chronic disorders, such as cardiovascular diseases, Rheumatoid Arthritis and cancer are anticipated to facilitate the growth of the market.



Scope of the Report:

  • The report presents the analysis of Rheumatoid Arthritis market for the historical period of 2016-2020 and the forecast period of 2021-2026.
  • The report analyses the Rheumatoid Arthritis Market by value (USD Million).
  • The report analyses the Rheumatoid Arthritis Market By Drug Type – NSAID(non-steroidal anti-inflammatory drugs), DMARD'S(Disease-modifying anti-rheumatic drug), Corticosteroids, Others.
  • The report analyses the Rheumatoid Arthritis Market by Treatment – Tendon Repair, Joint Fusion, Joint Replacement, Others.
  • The report analyses the Rheumatoid Arthritis Market By Diagnosis – CRP (Creative Protein Test), ESR (Erythrocyte Sedimentation Rate), Others.
  • The Global Rheumatoid Arthritis Market has been analysed by countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India).
  • Also, the attractiveness of the market has been presented by region, by Drug Type, by Treatment, By Diagnosis.
  • Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
  • The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Merck KGaA, Sanofi, Eli Lilly Company, Amgen Inc., Bristol-Mayor Squibb, F. Hoffman-La Roche Ltd., Johnson & Johnson, Cipla, Pfizer, Galapagos NV, Gilead Sciences.

Key Target Audience:

  • Pharmaceutical Companies
  • Consulting and Advisory Firms
  • Government and Policy Makers
  • Regulatory Authorities
Note: Product cover images may vary from those shown

1. Report Scope and Methodology
1. Report scope & Methodology
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. Strategic Recommendations3. Rheumatoid Arthritis Market: Product Outlook
4. Global Rheumatoid Arthritis Market: Sizing and Forecast
4.1 Global Rheumatoid Arthritis Market Size, By Value, Year 2016-2026
4.2 Impact of COVID-19 on Global Rheumatoid Arthritis Market
5. Global Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis
5.1 Competitive Scenario of Global Rheumatoid Arthritis Market: By Drug Type
5.1.1 NSAID (non-steroidal anti-inflammatory drugs) - Market Size and Forecast (2016-2026)
5.1.2 DMARD'S (Disease-modifying anti-rheumatic drug) - Market Size and Forecast (2016-2026)
5.1.3 Corticosteroids- Market Size and Forecast (2016-2026)
5.1.4 Others - Market Size and Forecast (2016-2026)
5.2 Competitive Scenario of Global Rheumatoid Arthritis Market: By Treatment
5.2.1 Tendon Repair - Market Size and Forecast (2016-2026)
5.2.2 Joint Fusion- Market Size and Forecast (2016-2026)
5.2.3 Joint Replacement- Market Size and Forecast (2016-2026)
5.2.4 Others - Market Size and Forecast (2016-2026)
5.3 Competitive Scenario of Global Rheumatoid Arthritis Market: By Diagnosis
5.3.1 CRP (Creative Protein Test) - Market Size and Forecast (2016-2026)
5.3.2 ESR (Erythrocyte Sedimentation Rate)- Market Size and Forecast (2016-2026)
5.3.3 Others - Market Size and Forecast (2016-2026)
6. Global Rheumatoid Arthritis Market: Regional Analysis
6.1 Competitive Scenario of Global Rheumatoid Arthritis Market: By Region
7. Americas Rheumatoid Arthritis Market: Segmentation (By Drug Type, By Treatment, By Diagnosis)
7.1 Americas Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value
7.2 Americas Rheumatoid Arthritis Market - Prominent Companies
7.3 Market Segmentation By Drug Type (DMARD’s, NSAID, Corticosteroid, Others)
7.4 Market Segmentation By Treatment (Tendon Repair, Joint Fusion, Joint Replacement and Others)
7.5 Market Segmentation By Diagnosis (CRP, ESR and Others)
7.6 Americas Rheumatoid Arthritis Market: Country Analysis
7.7 Market Opportunity Chart of Americas Rheumatoid Arthritis Market - By Country, By Value, 2026
7.8 Competitive Scenario of Americas Rheumatoid Arthritis Market: By Country
7.9 United States Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value
7.10 United States Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)
7.11 Canada Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value
7.12 Canada Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)
8. Europe Rheumatoid Arthritis Market: Segmentation (By Drug Type, By Treatment, By Diagnosis)
8.1 Europe Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value
8.2 Europe Rheumatoid Arthritis Market - Prominent Companies
8.3 Market Segmentation By Drug Type (DMARD’s, NSAID, Corticosteroids, Others)
8.4 Market Segmentation By Treatment (Tendon Repair, Joint Fusion, Joint Replacement and Others)
8.5 Market Segmentation By Diagnosis (CRP, ESR and Others)
8.6 Europe Rheumatoid Arthritis Market: Country Analysis
8.7 Market Opportunity Chart of Europe Rheumatoid Arthritis Market - By Country, By Value, 2026
8.8 Competitive Scenario of Europe Rheumatoid Arthritis Market: By Country
8.8 Germany Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value
8.10 Germany Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)
8.11 United Kingdom Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value
8.12 United Kingdom Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)
8.13 France Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value
8.14 France Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)
8.15 Italy Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value
8.16 Italy Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)
8.17 Spain Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value
8.18 Spain Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)
9. Asia Pacific Rheumatoid Arthritis Market: Segmentation (By Drug Type, By Treatment, By Diagnosis)
9.1 Asia Pacific Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value
9.2 Asia Pacific Rheumatoid Arthritis Market - Prominent Companies
9.3 Market Segmentation By Drug Type (DMARD’s, NSAID, Corticosteroidsand Others)
9.4 Market Segmentation By Treatment (Tendon Repair, Joint Fusion, Joint Replacement and Others)
9.5 Market Segmentation By Diagnosis (CRP, ESR and Others)
9.6 Asia Pacific Rheumatoid Arthritis Market: Country Analysis
9.7 Market Opportunity Chart of Asia Pacific Rheumatoid Arthritis Market - By Country, By Value, 2026
9.8 Competitive Scenario of Asia Pacific Rheumatoid Arthritis Market: By Country
9.9 China Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value
9.10 China Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)
9.11 Japan Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value
9.12 Japan Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)
9.13 India Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value
9.14 India Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)
10. Global Rheumatoid Arthritis Market Dynamics
10.1 Drivers
10.2 Restraints
10.3 Trends
11. Market Attractiveness
11.1 Market Attractiveness Chart of Global Rheumatoid Arthritis Market - By Drug Type, 2026
11.2 Market Attractiveness Chart of Global Rheumatoid Arthritis Market - By Treatment, 2026
11.3 Market Attractiveness Chart of Global Rheumatoid Arthritis Market - By Diagnosis, 2026
11.4 Market Attractiveness Chart of Global Rheumatoid Arthritis Market - By Region, 2026
12. Competitive Landscape
12.1 Product Pipeline of Leading Rheumatoid Arthritis Companies
12.2 Market Share Analysis
13. Company Analysis
13.1 Merck KGaA
13.2 Sanofi
13.3 Eli Lilly Company
13.4 Amgen Inc.
13.5 Bristol-Mayor Squibb
13.6 F. Hoffman-La Roche Ltd
13.7 Johnson & Johnson
13.8 Cipla
13.9 Pfizer
13.10 Galapagos NV
13.11 Gilead Sciences
List of Figures
  • Global Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)
  • Global Expenses (% GDP), 2015-2019
  • GDP per Capita Growth (annual %), 2015-2019
  • World Population 65 Years & Above (% of Total), 2015-2019
  • Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
  • Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
  • Global Rheumatoid Arthritis Market- By Drug Type Market Share, 2020 & 2026
  • Global Rheumatoid Arthritis Market- By NSAID, By Value (USD Million), 2016-2026
  • Global Rheumatoid Arthritis Market- By DMARD’S, By Value (USD Million), 2016-2026
  • Global Rheumatoid Arthritis Market- By Corticosteroids, By Value (USD Million), 2016-2026
  • Global Rheumatoid Arthritis Market- By Others, By Value (USD Million), 2016-2026
  • Global Rheumatoid Arthritis Market- By Treatment Market Share, 2020 & 2026
  • Global Rheumatoid Arthritis Market- By Tendon Repair, By Value (USD Million), 2016-2026
  • Global Rheumatoid Arthritis Market- By Joint Fusion, By Value (USD Million), 2016-2026
  • Global Rheumatoid Arthritis Market- By Joint Replacement, By Value (USD Million), 2016-2026
  • Global Rheumatoid Arthritis Market- By Others, By Value (USD Million), 2016-2026
  • Global Rheumatoid Arthritis Market- By Diagnosis Market Share, 2020 & 2026
  • Global Rheumatoid Arthritis Market- By CRP, By Value (USD Million), 2016-2026
  • Global Rheumatoid Arthritis Market- By ESR, By Value (USD Million), 2016-2026
  • Global Rheumatoid Arthritis Market- By Others, By Value (USD Million), 2016-2026
  • Global Rheumatoid Arthritis Market- By Region Market Share, 2020 & 2026
  • Americas Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)
  • Americas Biologic medicine share of total pharmaceutical sales, 2018 (Share of sales in %)
  • North America Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
  • North America Population ages 65 and above (% of total Population), 2016-2020
  • Americas Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026
  • Americas Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026
  • Americas Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026
  • Market Opportunity Chart of Americas Rheumatoid Arthritis Market- By Country, By Value (Year 2016-2026)
  • Americas Rheumatoid Arthritis Market- By Country Market Share, 2020 & 2026
  • United States Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)
  • United States Current health expenditure per capita (current USD), 2014-18
  • United States Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
  • United States Population aged 65 and above (% of total Population), 2016-2020
  • United State Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026
  • United State Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026
  • United State Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026
  • Canada Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)
  • Canada Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
  • Canada Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
  • Canada Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
  • Canada Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026
  • Canada Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026
  • Canada Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026
  • Europe Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)
  • Europe Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
  • Europe Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
  • European Countries Population ages 65 and above (% of total Population), 2020
  • Europe Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026
  • Europe Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026
  • Europe Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026
  • Market Opportunity Chart of Europe Rheumatoid Arthritis Market- By Country, By Value (Year 2016-2026)
  • Europe Rheumatoid Arthritis Market- By Country Market Share, 2020 & 2026
  • Germany Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)
  • Germany Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
  • Figure 56: Germany Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
  • Germany Urban population, 2015-2019 (In %)
  • Germany Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026
  • Germany Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026
  • Germany Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026
  • United Kingdom Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)
  • United Kingdom Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
  • United Kingdom Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
  • United Kingdom Population ages 65 and above (% of total Population), 2016-20
  • United Kingdom Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026
  • United Kingdom Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026
  • United Kingdom Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026
  • France Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)
  • France Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
  • France Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
  • France Population ages 65 and above (% of total Population), 2016-20
  • France Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026
  • France Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026
  • France Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026
  • Italy Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)
  • Italy Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
  • Italy Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
  • Italy Population ages 65 and above (% of total Population), 2016-20
  • Italy Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026
  • Italy Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026
  • Italy Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026
  • Spain Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)
  • Spain Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
  • Spain Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
  • Spain Germany Urban population, 2015-2019 (In %)
  • Spain Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026
  • Spain Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026
  • Spain Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026
  • Asia Pacific Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)
  • Asia Pacific Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
  • Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
  • Asia Pacific Population ages 65 and above, by Countries (% of total Population), 2020
  • Asia Pacific Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026
  • Asia Pacific Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026
  • Asia Pacific Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026
  • Market Opportunity Chart of APAC Rheumatoid Arthritis Market- By Country, By Value (Year-2026)
  • APAC Rheumatoid Arthritis Market- By Country Market Share, 2020 & 2026
  • China Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)
  • China Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
  • China Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
  • China Population ages 65 and above (% of total Population), 2016-20
  • China Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026
  • China Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026
  • China Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026
  • Japan Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)
  • Japan Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
  • Japan Current Healthcare Expenditure as percentage of GDP, 2015-2018 (In %)
  • Japan Population ages 65 and above (% of total Population), 2016-20
  • Japan Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026
  • Japan Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026
  • Japan Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026
  • India Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)
  • India Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
  • India Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
  • India Population ages 65 and above (% of total Population), 2016-20
  • India Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026
  • India Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026
  • India Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026
  • Market Attractiveness Chart of Global Rheumatoid Arthritis Market- By Drug Type (Year-2016-2026)
  • Market Attractiveness Chart of Global Rheumatoid Arthritis Market- By Treatment (Year 2016-2026)
  • Market Attractiveness Chart of Global Rheumatoid Arthritis Market- By Diagnosis (Year 2016-2026)
  • Market Attractiveness Chart of Global Rheumatoid Arthritis Market- By Region (Year 2016-2026)
  • Global Rheumatoid Arthritis company market share (%), 2020
  • Merck KGaA Sales Revenues, 2016-2020 (USD Million)
  • Merck KGaA Gross Profit, 2016-2020 (USD Million)
  • Merck KGaA Sales Revenue Split, By Business Segment (%), FY2020
  • Merck KGaA Sales Revenue Split, By Geography Segment (%), FY2020
  • Sanofi Sales Revenues, 2016-2020 (USD Million)
  • Sanofi Gross Profit, 2016-2020 (USD Million)
  • Sanofi Sales Revenue Split, By Business Segment (%), FY2020
  • Sanofi Sales Revenue Split, By Geography Segment (%), FY2020
  • Eli Lilly and Company Annual Sales Revenue (USD Million), 2016-2020
  • Eli Lilly and Company Annual Net Income (USD Million), 2016-2020
  • Eli Lilly and Company Sales Revenue Split, By Business Segment (USD Million), FY2020
  • Eli Lilly and Company Sales Revenue Split, By Geography Segment (%), FY2020
  • Amgen Inc. Sales Revenues, 2016-2020 (USD Million)
  • Amgen Inc. Net Income, 2016-2020 (USD Million)
  • Amgen Inc. Sales Revenue Split, By Business Segment (%), FY2020
  • Amgen Inc. Sales Revenue Split, By Geography Segment (%), FY2020
  • Bristol-Myers Squibb Sales Revenues, 2016-2020 (USD Million)
  • Bristol-Myers Squibb Net Income, 2016-2020 (USD Million)
  • Bristol-Myers Squibb Sales Revenue Split, By Business Segment (%), FY2020
  • Bristol-Myers Squibb Sales Revenue Split, By Geography Segment (%), FY2020
  • F. Hoffman-La Roche Ltd. Sales Revenues, 2016-2020 (USD Million)
  • F. Hoffman-La Roche Ltd. Net Income, 2016-2020 (USD Million)
  • F. Hoffman-La Roche Ltd. sales Revenues, By Business Segment (%), FY2020
  • F. Hoffman-La Roche Ltd. sales Revenue, By Geographical Segment (%), FY2020
  • Johnson & Johnson Annual Sales Revenue (USD Billion), 2016-2020
  • Johnson & Johnson Annual Net Income/Loss (USD Billion), 2016-2020
  • Johnson & Johnson Sales Revenue Split, By Business Segment (%), FY2020
  • Johnson & Johnson Sales Revenue Split, By Geography Segment (%), FY2020
  • Cipla Sales Revenues, 2016-2020 (USD Million)
  • Cipla sales Revenues, By Business Segment (%), FY2020
  • Cipla sales Revenue, By Geographical Segment (%), FY2020
  • Pfizer Annual Sales Revenue (USD Million), 2016-2020
  • Pfizer Annual Net Income/Loss (USD Million), 2016-2020
  • Pfizer sales Revenue, By Geographical Segment (%), FY2020
  • Galapagos NV Annual Sales Revenue (USD Million), 2016-2020
  • Galapagos NV sales Revenue, By Geographical Segment (%), FY2020
  • Gilead Sciences Annual Sales Revenue (USD Million), 2016-2020
  • Gilead Sciences Annual Net Income (USD Million), 2016-2019
Note: Product cover images may vary from those shown

Loading
LOADING...